Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours

被引：0

作者：

Lu, S. ^{[1
]}

De Braud, F. G. M. ^{[2
]}

Fan, Y. ^{[3
]}

Hu, X. ^{[4
]}

Ohe, Y. ^{[5
]}

Yu, Y. ^{[6
]}

Ahn, M-J. ^{[7
]}

Cassier, P. ^{[8
]}

Lin, J. J. ^{[9
]}

Paz-Ares, L. ^{[10
]}

Xue, C. ^{[11
]}

Bordogna, W. ^{[12
]}

Patel, S. ^{[13
]}

Zeuner, H. ^{[12
]}

Dong, X. ^{[14
]}

机构：

[1] Shanghai Jiao Tong Univ, Dept Med Oncol, Shanghai Chest Hosp, Shanghai, Peoples R China

[2] Univ Milan, Med Oncol & Haematol Dept, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] Zhejiang Canc Hosp, Dept Med Thorac Oncol, Hangzhou, Peoples R China

[4] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China

[5] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[6] Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Peoples R China

[7] Sungkyunkwan Univ, Sch Med, Dept Med, Seoul, South Korea

[8] Ctr Leon Berard, Dept Med, Lyon, France

[9] Massachusetts Gen Hosp, Ctr Thorac Canc, Boston, MA USA

[10] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[11] F Hoffmann La Roche Ltd, Biostat, Mississauga, ON, Canada

[12] F Hoffmann La Roche Ltd, Prod Dev Med Affairs, Basel, Switzerland

[13] Genentech Inc, Prod Dev Oncol, South San Francisco, CA USA

[14] Huazhong Univ Sci & Technol, Canc Ctr, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1852

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

666P

引用

页码：S468 / S469

页数：2

共 50 条

[1] Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
Bazhenova, L.
Liu, S. V.
Lin, J. J.
Lu, S.
Drilon, A.
Chawla, S. P.
Fakih, M.
Krzakowski, M.
Paz-Ares, L.
Blakely, C.
Buchschacher, G. L., Jr.
Cassier, P.
Fan, Y.
Folprecht, G.
McCallum, S.
Pitcher, B.
Chen, D.
Freund, R.
Springfeld, C.
ANNALS OF ONCOLOGY, 2021, 32 : S598 - S599
[2] Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
Krzakowski, Maciej Jerzy
Lu, Shun
Cousin, Sophie
Smit, Egbert F.
Springfeld, Christoph
Goto, Koichi
Garrido, Pilar
Chung, Christine H.
Lin, Jessica Jiyeong
Bray, Victoria J.
Pitcher, Bethany
Zeuner, Harald
Patel, Siddhartha
Bordogna, Walter
Gelderblom, Hans
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC
Cho, B. C.
Chiu, C-H.
Massarelli, E.
Chawla, S. P.
Buchschacher, G. L., Jr.
Goto, K.
Kim, S-W.
Overbeck, T. R.
Loong, H. H. F.
Chee, C. E.
Garrido, P.
Heinzmann, S.
Pitcher, B.
John, T.
ANNALS OF ONCOLOGY, 2022, 33 : S82 - S83
[4] Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Murakami, H.
Ohe, Y.
Hayashi, H.
Esaki, T.
Yamaguchi, T.
Fukuhara, T.
Daga, H.
Tanaka, H.
Kozuki, T.
Osborne, S.
Bordogna, W.
Goto, K.
ANNALS OF ONCOLOGY, 2022, 33 : S1594 - S1594
[5] Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/ metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC)
Cho, Byoung Chul
Chiu, Chao-Hua
Massarelli, Erminia
Buchschacher, Gary L.
Goto, Koichi
Overbeck, Tobias R.
Loong, Herbert H. F.
Chee, Cheng E.
Garrido, Pilar
Heinzmann, Sebastian
Bordogna, Walter
Zeuner, Harald
Osborne, Stuart
John, Tom
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2
Liu, Stephen V.
Peeters, Marc
Ahn, Myung-Ju
Lin, Jessica J.
Ohe, Yuichiro
Yau, Chung Cheung Thomas
Bordogna, Walter
Osborne, Stuart
Schwemmers, Sven
Zeuner, Harald
Goto, Koichi
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[7] Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Demetri, George D.
De Braud, Filippo
Drilon, Alexander
Siena, Salvatore
Patel, Manish R.
Cho, Byoung Chul
Liu, Stephen, V
Ahn, Myung-Ju
Chiu, Chao-Hua
Lin, Jessica J.
Goto, Koichi
Lee, Jeeyun
Bazhenova, Lyudmila
John, Thomas
Fakih, Marwan
Chawla, Sant P.
Dziadziuszko, Rafal
Seto, Takashi
Heinzmann, Sebastian
Pitcher, Bethany
Chen, David
Wilson, Timothy R.
Rolfo, Christian
CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1302 - 1312
[8] Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Lu, S.
Chiu, C-H.
Yu, Y.
Loong, H. H. F.
Lin, C. C.
Hu, X.
Dong, X.
Li, J.
Zhao, J.
Ye-Hui, S.
Zhang, Z.
Zhao, N.
Xia, J.
Wang, D.
Fan, Y.
ANNALS OF ONCOLOGY, 2022, 33 : S83 - S84
[9] Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC
Tan, D. S. W.
Ahn, M-J.
Chiu, C-H.
Ohe, Y.
Loong, H. H. F.
Chee, C. E.
Kim, S-W.
Takeda, M.
Li, Y-C.
Cheng, A.
Hida, T.
Kim, D-W.
Nogami, N.
Su, W-C.
Tanaka, H.
Osborne, S.
Freund, R.
Chen, D.
Seto, T.
ANNALS OF ONCOLOGY, 2020, 31 : S1358 - S1359
[10] Efficacy and safety of entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer
Lu, Janice
Blakely, Collin M.
Le Tourneau, Christophe
Waqar, Saiama N.
Bauer, Todd M.
de Braud, Filippo
Hong, David S.
Spira, Alexander
Tan, Tira
McCallum, Samuel
Osborne, Stuart
Simmons, Brian
Barve, Minal
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →